Copyright
©The Author(s) 2022.
Artif Intell Gastroenterol. Oct 28, 2022; 3(4): 105-116
Published online Oct 28, 2022. doi: 10.35712/aig.v3.i4.105
Published online Oct 28, 2022. doi: 10.35712/aig.v3.i4.105
Table 1 Patients' characteristics (n = 29)
Male/Female | 16/13 |
Age (yr) | 56.4 ± 14.3 |
Body weight (kg) | 74.1 ± 13.1 |
BMI (kg/m2) | 28.4 ± 5.2 |
Metabolic diseases | |
Diabetes mellitus (Yes/No) | 10/19 |
Dyslipidemia (Yes/No) | 14/15 |
Concomitant drugs | |
SGLT2 inhibitor | 2 |
DPP-4 inhibitor | 3 |
Thiazolidinedione | |
GLP-1 agonist | 1 |
Statin | 7 |
Bezafibrate | |
Pemafibrate | |
EPA and DHA preparation | 1 |
AST (U/L) | 50.2 ± 33.4 |
ALT (U/L) | 53.8 ± 39.0 |
GGT (U/L) | 80.3 ± 84.3 |
T-B (mg/dL) | 1.3 ± 0.9 |
Alb (mg/dL) | 4.2 ± 0.6 |
eGFR (mL/min) | 71.1 ± 11.5 |
HbA1c (%) | 6.4 ± 0.8 |
T-cho (mg/dL) | 191.3 ± 35.0 |
TG (mg/dL) | 126.5 ± 57.8 |
WBC (103/μL) | 5.6 ± 1.5 |
Hb (g/dL) | 14.5 ± 1.7 |
Plts (104/μL) | 17.7 ± 7.4 |
Table 2 Changes of blood biochemistry parameters and body weight
Baseline | 6M Follow-up | P value | |
AST (U/L) | 50.2 ± 33.4 | 34.7 ± 14.7 | 0.0088 |
ALT (U/L) | 53.8 ± 39.0 | 35.3 ± 16.8 | 0.0113 |
GGT (U/L) | 80.3 ± 84.3 | 66.3 ± 82.9 | 0.0494 |
HbA1c (%) | 6.4 ± 0.8 | 6.2 ± 0.6 | 0.27832 |
T-cho (mg/dL) | 191.3 ± 35.0 | 189 ± 34.3 | 0.2109 |
TG (mg/dL) | 126.5 ± 57.8 | 104.1 ± 60.6 | 0.0426 |
Body weight (kg) | 74.0 ± 13.1 | 71.2 ± 12.3 | 0.0472 |
Table 3 Number of photographed food items, analysis rate, and time for confirmation
Case | All foods | No of candidates | Analysis rate (%) | Time for confirmation (min) |
1 | 57 | 13 | 77.2 | 25.0 |
2 | 31 | 2 | 93.5 | 4.5 |
3 | 90 | 31 | 65.6 | 67.0 |
4 | 40 | 7 | 82.5 | 20.5 |
5 | 74 | 20 | 73.0 | 31.0 |
6 | 69 | 1 | 98.6 | 6.0 |
7 | 24 | 3 | 87.5 | 9.5 |
8 | 20 | 9 | 55.0 | 12.0 |
9 | 47 | 9 | 80.9 | 28.5 |
10 | 87 | 29 | 66.7 | 35.5 |
11 | 26 | 12 | 53.8 | 14.0 |
12 | 35 | 8 | 77.1 | 10.0 |
13 | 85 | 25 | 70.6 | 36.5 |
14 | 95 | 8 | 91.6 | 8.5 |
15 | 53 | 15 | 71.7 | 20.0 |
16 | 84 | 32 | 61.9 | 39.5 |
17 | 77 | 13 | 83.1 | 14.0 |
18 | 51 | 7 | 86.3 | 13.0 |
19 | 33 | 16 | 51.5 | 20.0 |
20 | 103 | 9 | 91.3 | 19.5 |
21 | 32 | 6 | 81.3 | 5.5 |
22 | 68 | 25 | 63.2 | 32.5 |
23 | 88 | 30 | 65.9 | 50.0 |
24 | 41 | 18 | 56.1 | 66.0 |
25 | 74 | 22 | 70.3 | 36.0 |
26 | 104 | 16 | 84.6 | 34.0 |
27 | 84 | 22 | 73.8 | 47.5 |
28 | 83 | 13 | 84.3 | 25.5 |
29 | 61 | 13 | 78.7 | 20.5 |
Average | 62.6 | 15.0 | 75.1 | 25.9 |
Table 4 Questionnaire results
Question | Yes | No |
1 | 29 | 0 |
2 | 15 | 14 |
3 | 29 | 0 |
4 | 25 | 29 |
- Citation: Kusano Y, Funada K, Yamaguchi M, Sugawara M, Tamano M. Dietary counseling based on artificial intelligence for patients with nonalcoholic fatty liver disease. Artif Intell Gastroenterol 2022; 3(4): 105-116
- URL: https://www.wjgnet.com/2644-3236/full/v3/i4/105.htm
- DOI: https://dx.doi.org/10.35712/aig.v3.i4.105